Serving patients and  transforming lives

Antibody engineering for promising drugs

A hope for finding a better tomorrow

Innovative research.  Transformative results.

Pioneering treatments for unmet needs

Dedicated to providing quality of life

What we do

NovelMed Therapeutics is a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process.  With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting acute and chronic diseases with large market potential and unmet medical need. We specialize in complement-based therapies.  Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates. Our portfolio of therapeutic antibodies target non-orphan and orphan diseases and have the potential for a better safety and efficacy profile than currently marketed drugs.
learn more

Research & development

NovelMed utilizes a unique R&D strategy which enables it to develop and evaluate antibodies that target specific proteins and processes within the complement system pathways.  Our portfolio of antibodies are filtered through a unique research pattern to identify best-fit candidates for further development to treat specific clinical indications. We have achieved remarkable success in advancing multiple antibodies that have a unique and superior mechanism of action compared to known alternative research and commercial programs. Our preclinical studies provide compelling evidence that these antibodies are likely to have a much higher level of efficacy than competing antibody therapies.  Moreover, our antibodies have the potential to be safer and have much easier dosing profile. We have generated significant pre-clinical data for commercialization of our drugs for the following indications:
learn more

Product Pipeline

Explore our Science